Two Sigma Advisers
ACRV icon

Two Sigma Advisers’s Acrivon Therapeutics ACRV Stock Holding History

Two Sigma Advisers’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-333,773
Closed -$804K – 30
2025
Q4 		$804K Buy
333,773
+197,273
+145% +$429K ﹤0.01% 1594
2025
Q3 		$247K Buy
136,500
+103,900
+319% +$146K ﹤0.01% 2061
2025
Q2 		$38.8K Buy
+32,600
New +$44.7K ﹤0.01% 2269

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's ACRV Position: Q1 2026 in Review

Two Sigma Advisers sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 333,773 shares — an estimated $804K sold.

Two Sigma Advisers first reported a position in ACRV in Q2 2025 and held it in 3 quarters. The position peaked at $804K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Two Sigma Advisers reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 333,773 Acrivon Therapeutics shares in Q1 2026, an estimated $804K.
  • Two Sigma Advisers first reported a position in Acrivon Therapeutics in Q2 2025 and held it in 3 quarters.
  • Two Sigma Advisers's Acrivon Therapeutics position peaked at $804K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.